Phase 2 winners
Five Phase 2 winners were each awarded $265,000 for their refined solutions for detecting active Lyme disease infections in people.
Winners
A molecular diagnostic blood test for Lyme B. burgdorferi s.l. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.
A small-volume serum test using glycan biomarkers to detect active Lyme disease infection and track treatment response.
An ultrasensitive, automated test to detect and identify active Lyme Borreliosis, direct from blood, in three hours.
A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.
A test using monoclonal antibodies in conjunction with both immuno-PCR and lateral flow to rapidly detect a unique B. burgdorferi biomarker in blood and urine.
(led by Jutras Lab, now at Northwestern University, Feinberg School of Medicine.)
Phase 1 winners
Ten Phase 1 winners were recommended by the LymeX Diagnostics Prize judging panel. Each winner was awarded $100,000 and received an exclusive invitation to participate in Phase 2.
A molecular diagnostic blood test for Lyme B. burgdorferi s.l. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.
A small-volume serum test using glycan biomarkers to detect active Lyme disease infection, track treatment response, and distinguish between diseases with similar symptoms.
A urine direct test that targets absolutely specific protein molecules and would provide direct information about pathogen activity.
A test combining novel sample preparation and artificial nucleic acid detection to identify active infection in whole blood, synovial fluid, and cerebrospinal fluid.
An automated, quantified, array-based serum test using machine learning to improve sensitivity in categorizing specimens.
Massachusetts General Hospital
Cell-free Target Capture Sequencing for the Diagnosis of Lyme Disease.
A plasma test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.
A universal multiplex serum test that incorporates patient-centric surveillance testing, population data, and machine learning to enhance understanding of tick-borne diseases.
A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.
A serum test targeting a unique antibody that would more accurately identify early infection and allow clinicians to optimize additional treatment.
A test using monoclonal antibodies in conjunction with immuno-PCR to detect a unique B. burgdorferi biomarker in multiple biofluids.
(led by Jutras Lab, now at Northwestern University, Feinberg School of Medicine.)